Turning off wakefulness
Actelion Ltd. thinks that its orexin receptor antagonist may offer people suffering from insomnia faster onset of action and better sleep architecture than products that work through other targets. The company highlighted Phase II data for the compound during its recent R&D day.
Orexin originally was thought to be involved in obesity. But, in